drugset / Trial / NCT00587847

Campath Maintenance in Chronic Lymphocytic Leukemia

NCT00587847

Terminated 12 enrolled Northwell Health Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a study designed to test whether giving campath (also known as alemtuzumab) on a maintenance schedule will prolong the time until the patient requires chemotherapy.

Timeline

Start
2005-08
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody 30 mg Subcutaneous